Table 3.
Lymphocyte subsets in healthy controls, SARIFA-positive and SARIFA-negative CRC patients.
| Healthy Controls n = 27 |
SARIFA-Positive n = 15 |
SARIFA-Negative n = 30 |
p1 SARIFApos-SARIFAneg |
p2 Healthy-SARIFAneg |
p3 Healthy-SARIFApos |
|
|---|---|---|---|---|---|---|
| Total lymphocytes | 1795 (1195–2216) | 1388 (1185–1687) | 1288 (965–1623) | ns | 0.038 | ns |
| CD3+ cells | 1101 (671–1678) | 876 (783–1320) | 866 (714–1142) | ns | ns | ns |
| CD8+ cells | 228 (191–364) | 228 (184–397) | 233 (118–325) | ns | ns | ns |
| Naive | 48 (9–70) | 51 (33–83) | 25 (15–58) | ns | ns | ns |
| Memory | 102 (55–133) | 63 (39–124) | 84 (49–117) | ns | ns | ns |
| CM | 21 (4–40) | 24 (13–33) | 23 (13–55) | ns | ns | ns |
| EM | 79 (47–126) | 76 (35–148) | 72 (47–101) | ns | ns | ns |
| EMRA | 68 (23–134) | 69 (18–148) | 29 (16–110) | ns | ns | ns |
| Early | 160 (89–206) | 133 (94–165) | 78 (56–181) | ns | 0.025 | ns |
| Intermediate | 20 (10–30) | 13 (6–30) | 10 (6–24) | ns | ns | ns |
| Late | 36 (22–87) | 58 (42–201) | 51 (18–126) | ns | ns | ns |
| Exhausted | 81 (51–133) | 82 (29–114) | 53 (23–79) | ns | 0.019 | ns |
| Terminal effector | 21 (12–63) | 39 (15–135) | 31 (9–97) | ns | ns | ns |
| HLA-DR+ | 31 (10–45) | 92 (56–177) | 60 (36–112) | ns | 0.011 | 0.002 |
| CD69+ | 21 (17–46) | 19 (12–32) | 13 (7–24) | ns | 0.037 | ns |
| CD4+ cells | 634 (487–1042) | 547 (268–773) | 524 (406–640) | ns | ns | ns |
| Naive | 282 (143–371) | 218 (59–441) | 157 (117–239) | ns | ns | ns |
| Memory | 411 (255–552) | 311 (182–366) | 303 (234–386) | ns | ns | 0.027 |
| CM | 198 (91- 289) | 190 (109–250) | 190 (139–236) | ns | ns | ns |
| EM | 181 (98–268) | 99 (63–169) | 123 (82–163) | ns | ns | 0.05 |
| EMRA | 14 (1–44) | 4 (2–8) | 8 (1–26) | ns | ns | ns |
| Th1 | 28 (13–61) | 17 (14–33) | 19 (8–44) | ns | ns | ns |
| Th2 | 48 (34–81) | 40 (16–63) | 47 (33–60) | ns | ns | ns |
| Th17 | 67 (36–83) | 40 (17–70) | 48 (33–60) | ns | ns | ns |
| CD25high | 11 (6–18) | 10 (7–32) | 15 (9–24) | ns | ns | ns |
| HLA-DR+ | 39 (27–64) | 50 (34–62) | 51 (44–67) | ns | 0.011 | 0.002 |
| CD69+ | 12 (7–19) | 13 (11–21) | 14 (9–18) | ns | 0.037 | ns |
| NK cells | 189 (125–281) | 87 (59–117) | 187 (118–252) | 0.002 | ns | <0.001 |
| CD56dim CD16bright | 12 (9–19) | 6 (4–12) | 14 (8–25) | 0.004 | ns | 0.004 |
| CD56+ CD16+ | 162 (98–264) | 56 (36–90) | 151 (103–220) | <0.001 | ns | <0.001 |
| CD56bright CD16dim | 15 (10–19) | 10 (9–14) | 11 (8–15) | ns | ns | ns |
| NK-like T cells | 47 (18–83) | 47 (21–67) | 34 (17–134) | ns | ns | ns |
| B cells | 208 (146–236) | 122 (85–205) | 123 (62–165) | ns | <0.001 | ns |
| Naive | 116 (88–164) | 88 (58–152) | 69 (37–99) | ns | 0.006 | ns |
| Memory | 7 (5–9) | 8 (4–12) | 6 (2–15) | ns | ns | ns |
| Class switch | 25 (16–41) | 18 (12–21) | 11 (6–28) | ns | 0.002 | ns |
| Transitory | 7 (5–14) | 1 (1–2) | 2 (1–4) | ns | <0.001 | <0.001 |
| CD4/CD8 Ratio | 3 (2–4) | 2 (1–3) | 3 (2–4) | ns | ns | ns |
ns = not signficant (at p < 0.05). Significant p-values are highlighted in bold. Cell counts are given as median value/µL (interquartile range). p-values (adjusted) are given for pairwise comparisons using Wilcoxon test with Benjamini-Hochberg correction for following comparisons: p1) SARIFA-positive vs SARIFA-negative, p2) healthy controls vs SARIFA-negative, p3) healthy controls vs SARIFA-positive.